Pivotal study designs revealed
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Cargo can't replicate firi-cel's academic success
Firce-1 is scrapped after showing dismal response rates and patient deaths.
Zentalis doubles down on Wee1
But the new focus on a predictive biomarker could cut the market in half.
A Leap into the subgroups
On a wing and a prayer Leap heads for phase 3.
